Knowledge graph · Trial
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
RECRUITING
- Identifier
- CI-TRIAL-00122110
- Entity page
- /trial/NCT07196644 ↗
- Edges
- 0
- Neighbours
- none
- Drawn
- 0 of 0 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,147Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Data not yet available
No knowledge edge or registry link touches this trial on this environment. Edges appear once a source (CIViC, ChEMBL, openFDA, ClinicalTrials.gov, GDC) states one — CancerIndex does not infer them.
What CancerIndex knows
- Open A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
- Lung Non-Small Cell Carcinoma
- Malignant Colorectal Neoplasm
- ABL1
- EGFR